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1. ABSTRACT 
 
About 85% of multiple sclerosis (MS) cases start as clinically isolated syndrome (CIS). 
When patients present with a CIS, clinicians face with many questions, most of them 
related with prognosis and treatment. Thereby, patients with CIS have been focus of 
research. Several studies have demonstrated a relationship between positive IgM lipid-
specific oligoclonal band pattern in CSF and higher lesion load on MRI brain scan, higher 
number of relapses and greater disability, even at the first stages of the disease. On the 
other hand, no studies have used this previous evidence to treat with more aggressive 
disease modifying therapy in initial stages of disease course to prevent the earlier axonal 
damage. 
 
The aim of this study is to assess the most effective approved treatment for MS and 
current therapy for CIS patients presenting high risk to develop CDMS and with bio-
markers of poor prognosis. Among this group of patients any disease activity will 
eventually lead to disability. Therefore, the earlier the treatment is initiated, the more 
effective to prevent disability will be. It is considered that “time lost is brain lost” and since 
once damage is established, there is no therapy to be regained later on. 
 
In this phase III clinical trial, 172 patients will be randomized 1:1 to receive Interferon β-1b 
or natalizumab over 96 weeks. Time to develop clinical definitive multiple sclerosis 
(CDMS) will be included as primary endpoint. Other secondary endpoints will include 
clinical data, magnetic resonance imaging (MRI) measurements and quality of life tests.  
 
2. INTRODUCTION 
 
2.1 Epidemiology 
Multiple sclerosis (MS) is the most common chronic demyelinating disease of the central 
nervous system (CNS) and the second cause of disability in young adults after brain 
traumatic injuries. With unknown aetiology, there are several evidences to corroborate that 
it is an autoimmune disease [1, 2]. The prevalence of MS in Spain is between 40 and 125 
cases for 100.000 inhabitants depending on the studies and there is a female 
preponderance [2]. MS is between twice and three times more common in women than in 
men, and the global incidence is increasing [2, 3].  
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2.2 Risk factors 
Currently, the strongest genetic association for MS is the human leukocyte antigen (HLA) 
gene locus on chromosome 6, specifically certain HLA types as HLA DR15 and DQ6. 
These genes are involved in antigen recognition by T-cells and may therefore determine 
whether or not abnormal responses are made towards myelin proteins [2, 4, 5]. 
 
Large-scale epidemiological and migration studies indicate that certain environmental risk 
factors are associated with the development of MS. These factors are thought to affect the 
immune system and include: prior infection with Epstein-Barr virus, smoking and  vitamin D 
deficiency related to sunlight exposure or diet [4,5]. 
 
2.3 Pathogenesis  
The pathogenesis of MS comprises three different characteristics: inflammation, 
demyelination and axonal damage. 
 
Multiple sclerosis as an autoimmune disease: In genetically susceptible individuals, 
through a process of immune dysregulation and probably mistaken antigen identity, CD4 T-
cells become primed in the peripheral blood and cross the blood-brain barrier, where they 
recognize components of the myelin sheath. The subsequent release of cytokines 
activates macrophages and B-cells [2,4,6,7]. 
 
Multiple sclerosis as a demyelinating disease: Demyelination is a central feature of MS 
lesion pathology. There are different patterns of demyelination: T-cell and macrophage 
mediated, antibody mediated involving complement activation, oligodendrogliopathy, 
oligodendrocyte apoptosis and oligodendrocyte degeneration[2,6]. 
 
Multiple sclerosis as a neurodegenerative disease: Parallel to inflammatory phase 
associated with demyelization, axonal loss responsible for irreversible disability occurs 
already early in the disease course [2, 3, 4]. 
 
2.4 Diagnosis 
The diagnosis of MS is mainly clinical and it is based on the confirmation dissemination of 
lesions in time and space after the exclusion of other aetiologies. It requires the integration 
of clinical history, neurological examination, MRI scanning and the profile of cerebrospinal 
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fluid [8]. 
The McDonald criteria [9] were designed to simplify diagnosis and are the most used today 
both clinical practice and research. MRI is the most important diagnostic tool for 
demonstrating dissemination in time and space. 
 
2.5 Clinical course 
85% of MS patients present a relapsing-remitting course [2, 4]. It is characterized by 
relapses with focal neurological deficits than could improve totally or partially leaving 
sequels. With time, recovery from each episode is incomplete and persistent symptoms 
accumulate. Eventually, around 65% of patients enter to the secondary progressive phase 
of the disease [3]. In 15% of patients the clinical course is progressive from onset [2, 3]. 
 
Usually, (80-85%) the disease presents with a first attack. This initial episode of focal 
demyelination is known as a clinically isolated syndrome (CIS) [2,3]. However, not all CIS 
patients develop MS and its disability progression can be highly variable. In the last years, 
several studies have tried to find prognostic factors that might predict future disease 
course. These main prognostic factors are: 
 
 Number of lesions in the first MRI [10-12]. 
 Presence of IgG oliclonals bands in the CSF. They are present in nearly 95% of MS 
patients, for this reason it is a good tool to predict conversion to clinically definitive 
multiple sclerosis (CDMS) but not to predict the severity of the clinical course [14]. 
 Intrathecal IgM synthesis are present in nearly 40% of the CSF of MS patients and it 
is related with several factors of poor prognosis [13-19]: 
• The time to a second relapse after a CIS. 
• The time to reach disability (EDSS of 4.0). 
• The time to develop a secondary progressive phase of the disease. 
• The increases in early brain atrophy.  
• The increases in T2 lesion load.  
 
The most recent works have demonstrated that IgM against lipids are the specific IgMs 
which are related with an aggressive course and the involvement in plaque formation [13, 
14, 16, 17, 18,19]. 
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2.6 Treatment  
2.6.1 First-line of treatment 
The first line of treatment includes disease modifying drugs authorized for use after 
establishing the diagnosis. It is allowed to start treatment with any of them and they are 
also interchangeable whether it is considered [8, 21].  
 
Beta Interferons: Interferons are a family of pleiotropic cytokines produced by cells in 
response to viral infections. These cytokines exhibit antiviral, immunomodulatory and 
antitumor properties by regulating expression of hundreds of genes involved in biological 
processes such as cell cycle progression, cell proliferation and apoptosis [23]. The exact 
mechanism of action of IFN-β in MS is complex and is not clearly understood, it increases 
production of anti-inflammatory agents such as IL-10 and decreases production of pro-
inflammatory cytokines such as IL-17. It also inhibits immune cell trafficking across the 
blood–brain barrier and stimulates the production of trophic factors such as nerve growth 
factors [22-24]. There are differents forms of presentation (table I). 
 
Drug Brand  Recomended dose Dosing frequency Route 
Interferon beta-1a Avonex  30 mcg Once weekly IM 
Interferon beta-1a Rebif  22 or 44 mcg Three times weekly SQ 
Interferon beta-1b Betaferon 0,25 mg Every other day SQ 
Interferon beta-1b Extavia  0,25 mg Every other day SQ 
Taula 1: Interferons FDA approved. IM= intramuscular, SQ= subcutaneous 
 
Glatiramer Acetate: Glatiramer acetate (GA) is a polypeptide made up of four amino acids 
(L-glutamic acid, L-lysine, L-alanine, and L-tyrosine). Its mechanisms of action are not 
completely understood, but several studies indicate that GA causes an immune deviation 
from a Th1 to a Th2 phenotype, induces antigen-specific T suppressor cells that react with 
autoantigens in the CNS, and inhibits antigen presentation [24]. The form of presentation is 
route subcutaneous, once daily with 20 mg as a recommended dose [22]. 
 
2.6.2 Second-line of treatment 
In MS, a drug is considered as second-line when its use is subject to failure or intolerance 
of previous first-line treatments [8, 21]. 
 
Fingolimod: Fingolimod is a sphingosine-1-phosphate receptor modulator that is 
metabolized by sphingosine kinase to the active metabolite fingolimod phosphate, which 
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blocks the migration of lymphocytes from lymph nodes and reduces the number of 
lymphocytes in peripheral blood. The mechanism that is the basis of the therapeutic effect 
of fingolimod in MS is unknown, but it might involve the reduction of lymphocyte migration 
into the CNS [21-23]. 
 
Natalizumab: Natalizumab is a recombinant humanised monoclonal antibody that binds to 
the α4 subunit of 41 integrin (VLA-4) on the surface of lymphocytes. This action blocks the 
binding of the subunit to its receptor (VCAM-1), which is present in the endothelium. This 
action prevents lymphocytes from crossing blood brain barriers and entering in the central 
nervous system, reducing the pathological process of MS [21-23]. 
 
In a randomized, placebo-controled trial of natalizumab for relapsing multiple sclerosis [25] 
were enrolled 942 patients, 627 were assigned to receive natalizumab every 4 weeks and 
315 to receive placebo by intravenous . The study demonstrated the following aspects of 
efficacy: 
 Reduction the rate of clinical relapses at one year by 68% (p<0.001). 
 Reduction the risk of sustained progression of disability by 42% (hazard ratio 0.58 
CI (0.43 to 0.77). 
 Reduction in the accumulation of new or enlarging hyperintense lesions by 83% 
(p<0.001). 
 Reduction in gadolinium enhancing lesions by 92% (p<0.001).  
 
2.6.3 Natalizumab management 
Natalizumab is the most effective therapy at reducing relapses and delaying disease 
progression in MS [25]. On the other hand, this treatment has also been associated with a 
risk of progressive multifocal leukoenchephalopathy (PML). For this reason, its use needs 
to be considered carefully and established a benefit-risk balance [32]. 
 
On a practical level, currently there are 3 variables to stratify risk of PML (figure 1): 
• Presence/absence of anti-JC virus antibodies. 
• Presence/absence of previous immunosuppressive (IS) therapy. 
• Treatment duration in months: more than o less than 24 months. 
 
The treatment with natalizumab in this study will be over 2 years in order to have a 
   
7 
 
minimum risk to develop LMP. Also, a current study [30] has demonstrated in two 
independent cross-sectional and two longitudinal sets of patients that natalizumab 
decrease IgM and IgG levels within the first two years of therapy.  
 
  
 
 
 
 
 
 
Treatment 
duration 
Without 
previous IS 
With 
previous IS 
1-24 months 0.7/1000 1.8/1000 
25-48 monts 5.3/1000 11.2/1000 
Figure 1. Risk to develop LMP 
 
2.7 Current therapies for CIS  
CIS stage represents the first opportunity for treatment in patients with high risk of 
conversion to CDMS. In addition, the presence of early and irreversible axonal damage in 
CNS of MS patients apparently reduces the benefit of treatment afterwards. Several 
studies have corroborated treatment with disease-modifying therapies should begin early 
in the disease course [26, 27]. 
 
Three large clinical trials have shown that IFNβ treatments are effectiveness in CIS 
patients: 
 Controlled High-Risk Avonex MS prevention Study (CHAMPS). 
 Early treatment of MS (ETOMS). 
 Betaferon in newly emerging MS for initial treatment (BENEFIT). 
 
The CHAMPS study [28] enrolled 383 CIS randomized to two groups: 193 once-weekly 
IFNβ-1a versus 190 placebo injections. CDMS was defined by second attack or increase 
of at least 1.5 points on the EDSS. At 3 years, CDMS was lower in the IFNβ-1a group than 
in placebo (rate radio (rr) for the cumulative probability of CDMS = 0.56; p= 0.002). 
0.07/1000 
Negative Positive 
Anti-JCV antibody status 
Previous IS treatment 
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The ETOMS study [29] enrolled 309 CIS randomized to: 154 once-weekly injection of 
IFNβ-1a versus 155 placebo injections. The results was higher proportion of patients in 
placebo group than in IFNβ-1a group converted from CIS to CDMS over 2 years (rr for the 
cumulative probability of CDMS = 0.65; p= 0.047). 
 
In the BENEFIT [30] study were enrolled 468 patients: 292 IFNβ-1b versus 176 placebo. 
Over 2 years accumulative probability for CDMS was higher in placebo group (rr for the 
cumulative probability of CDMS = 0,5; p= 0,0001). 
 
Moreover, the study PRECISE [31] has shown that AG presents similar effectiveness than  
IFNβ in the prevention to develop from CIS to CDMS. For this reason, IFNβ and AG have 
a class A recommendation to prevent new relapses or new lesions on MRI in cases with 
high risk of conversion to CDMS (figure2). Health authorities have approved the indication 
of these drugs for the CIS treatment at the same dose and frequency than in RRMS form 
[21].  
 
                                                                                  CIS  
           
                                                          MS risk related to MRI brain 
 
  
 
 
 
    0 T2 lesions                     1-9 T2 lesions       <9 T2 lesions 
     0 Gd + lesion              0 Gd+ lesions       Gd+ lesions 
 
 
 
     Clinical and              Recommend starting        
     radiological                                      immunotherapy: 
                 observation         · IFNβ 
           · AG 
 
 
Figure 2. MRI risk to develop CDMS 
Depending on: 
- Multifocal onset 
- Extent of recovery 
- Spine MRI 
- Positive CSF 
- Patient preference 
Low risk Intermediate risk High risk 
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4. HYPOTHESIS 
 
Early natalizumab treatment in subjects with CIS and poor prognostiic factors will reduce 
the development of CDMS compared to interferon β-1b. 
 
Early natalizumab treatment in subjects with CIS and poor prognostic factors will reduce 
the disability progression and the frequency of relapses after CDMS compared to 
interferon β-1b. 
 
Early natalizumab treatment in subjects with CIS and poor prognostic factor will reduce the 
lesion load and brain atrophy compared to interferon β-1b. 
 
Early natalizumab treatment will improve the quality of life in patients with CIS and poor 
prognostic factors compared to interferon β-1b. 
5. OBJECTIVES 
5.1 Primary objective 
1. To assess natalizumab compared to interferon β-1b in reduction of CDMS in 
subjects with CIS and factors of poor prognosis over 96 weeks. 
5.2 Secondary objectives 
Clinical objectives: to assess the effect of natalizumab compared to Interferon β-1b on:  
2. Disability progression in subjects with CIS and poor prognosis factors over 96 
weeks. 
3. Frequency of relapses in subjects with CIS and poor prognostic factors over 96 
weeks. 
 
MRI objectives: to assess the effect of natalizumab compared to interferon β-1b on: 
4. Total volume of T2 hyperintense lesions over 96 weeks. 
5. Number of new gadolinium enhancing lesions over 96 weeks. 
6. Number of new T1 hypointense lesions over 96 weeks. 
7. Brain atrophy developed over 96 weeks. 
 
Quality of life objectives: to assess the effect of Natalizumab compared to Interferon β-1b 
on: 
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8. Fatigue. 
9. Health-related quality of life. 
6. METHODS 
6.1 Study design 
This is an interventional and multi-center study. The allocation will be randomized, the 
intervention model will be parallel assignment in 2 groups and the masking will be double 
blind. Study participants and observers will not know treatment assignments. 
The treatment duration is 96 weeks for the last patient recruited. The treatment period will 
have a fixed time of 96 weeks for all patients. For those patients who complete the 
treatment period, a follow up extension will have a minimum duration of 6 months in order 
to observe and detect potential side effects. 
6.2 Inclusion and exclusion criteria 
Inclusion criteria 
1. Age ranging from 18 to 55 years. 
2. Understanding and accepting the purpose and the risks of this study signing the 
informed consent. 
3. Must have a confirmed diagnosis of CIS according to both clinical and cranial MRI. 
4. Must have all the following risk factors to develop an aggressive CDMS: 
• 1-9 T2 hyperintense lesions and gadolinium enhancing lesions or more than 9. 
T2 hyperintense lesions. 
• Positive IgG and IgM-LS oligoclonal bands in CSF. 
5. Must have at most 1 risk factor of the following  to develop LMP: 
• Presence of anti-JC virus antibodies. 
• Presence of previous immunosuppressive (IS) therapy. 
• Treatment duration in months: more than 24 months. 
6. Baseline assessment, clinical, MRI and CSF performed less than 1 month from 
clinical onset. 
 
Exclusion criteria 
1. Diagnosis of MS in any disease course: relapsing-remitting, secondary progressive 
or primary progressive form. 
2. Diagnosis of radiological isolated syndrome (RIS). 
3. Diagnosis of CIS but without having all the following risk factors to develop an 
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aggressive CDMS: 
• 1-9 T2 hyperintense lesions and gadolinium enhancing lesions or more than 
9 T2 hyperintense lesions. 
• Positive IgG and IgM-LS oligoclonal bands in CSF. 
4. More than 1 risk factor to develop LMP. 
5. Liver function impairment or persisting elevations (confirmed by retest) of serum 
glutamic pyruvic transaminase (SGPT/ALT), serum glutamic oxaloacetic 
transaminase (SGOT/AST), or direct bilirubin greater than 3-5 fold the upper limit of 
normal. 
6. Known history of hepatitis B or C. 
7. Human immunodeficiency virus (HIV) positive patients. 
8. Previous history of major psychiatric or neurological disturbances. 
9. Women who are currently pregnant/ breast feeding or they want to be pregnant/ 
breast feeding over study period. 
 
6.3 Sample size  
Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a one-sided test, 86 subjects in the 
active intervention group with 60 conversions and 86 reference subjects with 60 
conversions are required, assuming that the conversion rate at 1, 12.5 and 24 moments 
among the reference subjects will be 0.1, 0.3 and 0.9 while in the active intervention group  
will be 0.02, 0.13 and 0.84 respectively. It has been anticipated a drop-out rate of 5%.  
 
6.4 Randomization and masking 
The patients will be randomized using a 1:1 randomization ratio between two groups: 
• Group 1: Nearly 86 patients. Natalizumab 300 mg infusion every 4 weeks plus 
placebo (sc) every-other day. 
• Group 2: Nearly 86 patients. Interferon β-1b 0.25 mg (sc) every-other day plus 
placebo infusion every 4 weeks. 
In order to assure blinding procedures, one neurologist will be the treating and another one 
will be the examining or blind neurologist.  
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6.5 Variables for the analysis of goals 
6.5.1 Primary endpoint 
The primary endpoint in this study is the time to develop CDMS. According to Mc Donald 
criteria, CDMS is defined as the occurrence of a new neurological event lasting more than 
24h and involving a different part of the brain at least 1 month after the end of a previous 
one. 
6.5.2 Clinical endpoints 
Disability progression will be assessed using EDSS [Annex I]. Sustained disability 
progression is defined as: 
• At least 1.0 point increase on the EDSS from baseline EDSS ≥ 1.0 that is sustained 
for 12 weeks. 
• At least 1.5 point increase on the EDSS from baseline EDSS = 0 that is sustained 
for 12 weeks. 
 
The relapses will be assessed using the annualized relapse rate (ARR). The ARR will be 
calculated as the total number of relapses in the treatment group divided by the number of 
days in the study, and the ratio multiplied by 365. 
 
 A relapse of multiple sclerosis is defined as the occurrence, the recurrence, or the 
worsening of symptoms of neurologic dysfunction that lasted more than 24 hours and that 
are stabilized or eventually resolved either partially or completely. Fatigue alone and 
transient fever-related worsening of symptoms are not considered relapses. Symptoms 
that occurred within a month after the initial symptoms of relapse are considered to be part 
of the same episode. 
 
• Each episode of relapse will be confirmed by the treating neurologist, based on the 
objective assessments by the examining neurologist. 
• Subjects will be instructed to contact their investigator immediately should any 
symptoms suggestive of an MS exacerbation appear.  
 
6.5.3 MRI endpoints 
The MS protocol of MRI brain scan include: T1 SE 3mm, DWI, Dual (proton density + T2), 
GM only, FLAIR and T1+Gd sequences. This protocol will be performed to assess: 
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• Total volume of T2 hyperintense lesions.  
• Number of new gadolinium enhancing lesions.  
• Number of new T1 hypointense lesions.  
• Brain atrophy.  
6.5.4 Quality of life endpoints 
Subject reported-fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS) 
[Annex II]. The MFIS is a validated specific subject-reported outcome measure that was 
developed to evaluate the impact of fatigue on the lives of people with MS. The instrument 
can be self-interviewer or telephone-administered and consists of a total score and 3 
subscales to assess the impact of fatigue on: 
• Cognitive function  
• Physical function  
• Psychosocial function  
 
The MFIS takes approximately 10 minutes to complete. 
 
Health-related quality of life will be assessed using the Multiple Sclerosis Quality of Life-54 
(MSQOL-54) [Annex III]. The MSQOL-54 is a multidimensional health-related quality of life 
measure that combines both generic and MS-specific items into a single instrument. This 
54-item instrument generates 12 subscales along with two summary scores, and two 
additional single-item measures. The subscales are: physical function, role limitations-
physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, 
social function, cognitive function, health distress, overall quality of life, and sexual 
function. The summary scores are the physical health composite summary and the mental 
health composite summary. The single item measures are satisfaction with sexual function 
and change in health.  
 
6.6 Statistical analysis 
Quantitative, parametric and continuous variables will be expressed as mean and standard 
deviation. Quantitative, continuous but non-parametric variables will be expressed as 
median and interquartile range. Qualitative variables will be described as percentages. 
 
Analysis of primary variable 
• Time to develop CDMS will be calculated using log-rank test as a first analysis and 
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adjusted by Cox proportional regression. 
 
Analysis of secondary variables 
• Time to confirmed EDSS progression will be calculated as the same manner of 
primary variable. 
• MRI results, FIS and MSQOL-54 scores will be analysed with non-parametric 
ANCOVA.  
 
6.7 Study procedures and data collection  
The visit schedule is performed with the following items: 
• Screening (from week - 4 to week 0).  
• Treatment period (from week 0 to week 96). 
• Randomization at baseline. 
• Clinical visits: will be performed every 4 weeks.  
• MRI: will be performed every 6 months. 
• Safety laboratory units: will be performed every 4 weeks between clinical 
visits until the end of the treatment period. 
• Follow up period: will be performed for 6 months after end of treatment. 
• Unscheduled visits: will be performed when MS relapse will be suspected. 
6.7.1 Screening 
The following items will be checked or performed and recorded: 
• Review of inclusion and exclusion criteria. 
• Clinical laboratories: haematology, coagulation, liver function, electrolytes levels, 
renal function, urinalysis panel and pregnancy test. 
• Informed consent for HIV testing and HIV test. 
• Determination of the EDSS score by the examining neurologist and review by the 
treating neurologist. 
• Determination of the number of lesions using MRI brain scan based on MS specific 
protocol. 
• Information on adverse events and informed consent signature. 
6.7.2 Randomization: 
Prior to randomization, the following items will be checked or performed and recorded: 
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• Verification of eligibility by review of inclusion and exclusion criteria. 
• Physical examination and vital signs. 
• Information on adverse events. 
• Clinical laboratories: haematology, coagulation, liver function, chemistry panel, renal 
function, urine analysis and pregnancy test.  
• Determination of the EDSS scores. 
• Measurement of the MFIS scores. 
• Measurement of the MSQOL-54 scores. 
 
After randomization the first dose of study drug endovenous will be administrated and a kit 
with study drug subcutaneous injections. In order to mask flu-like symptoms, 600 mg of 
Ibuprofen will be administrated 30 min before each injection as well as 6 hours afterwards. 
6.7.3 Treatment period 
The following assessments will be performed in the clinic visits: 
• Dispense study medication: Intravenous therapy and injections for subcutaneous 
therapy will be provided every 4 weeks. 
• Determination of the EDSS score by the examining neurologist and review by the 
treating neurologist at weeks: 0, 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96. 
• Determination of the MFIS and MSQOL-54 score at weeks: 24, 48, 72, 96. 
• MRI brain scan at week: 24, 48, 72 and 96. Determination of volume of T2 
hyperintense lesions, number of T1 hypointense lesions, number of gadolinium 
enhancing lesions and brain atrophy at week: 24, 48 and 96. In all MRI performed 
will be evaluated the presence/absence of LMP first signs.  
• Clinical laboratories: haematology, coagulation, liver function, chemistry panel, renal 
function and urinalysis panel will be performed every 4 weeks until week 96. Serum 
antibodies against natalizumab will be performed at week 24, 48, 72, 96. 
6.7.4 Unscheduled relapse visit 
The following items will be checked or performed and recorded: 
• A relapse will be confirmed by the examining neurologist and review by the treating 
neurologist. 
• If the patient had had a confirmed relapse: 
 Time since first dose of treatment. 
 The subject will have to sign the informed consent form for re-consent 
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to continue with the study.   
6.7.5 Follow up period 
In order to ensure the safety of all patients, the following items will be performed: 
• Clinical laboratories: liver function and haematology at week 108 and 120. 
• MRI brain scan at week 120 to evaluate the presence/absence of LMP first signs. 
 
7. LIMITATIONS OF THE STUDY 
The major limitation of this study is to achieve the estimated sample size. Mainly, this is 
due to: 
• Relatively low prevalence of CIS presentation with poor prognosis factors. 
• The IgM pattern band in CSF is positive in only 40% of patients. 
• Very restrictive inclusion criteria. 
• Patients will not want to participate for the risk of LMP, even though this is low. 
 
Other limitations are: 
• The side effects of the study drugs can impair the blinding process and induce a 
procedure bias. 
• The high cost to perform the study. 
  
8. TREATMENTS 
8.1 Natalizumab  
300 mg of natalizumab will be infused in 100 mL 0,9% sodium chloride injection over 
approximately one hour (infusion rate 5 mg/ min). After the infusion is complete, flush with 
0,9% sodium chloride injection. 
 
The patients will be observed during the infusion and for one hour after the infusion will be 
completed. The infusion will be promptly discontinued whether any signs or symptoms 
consistent with hypersensitivity-type reaction will be detected. 
 
8.1.1 Adverse effects 
The most common adverse reactions (incidence ≥ 10%) is headache, fatigue, arthralgia, 
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urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, 
depression, pain in extremity, abdominal discomfort, diarrhea and rash. 
8.1.2 Warnings and precautions 
Progressive multifocal leukoencephalopathy  
PML is an opportunistic viral infection of the brain caused by the JC virus that typically only 
occurs in patients who are immunocompromised, and that usually leads to death or severe 
disability. The risk to develop LMP in patients who are treated with natalizumab is 
explained in the section 2.6.2.2. 
 
Typical symptoms associated with PML are diverse, progress over days to weeks, and 
include progressive weakness on one side of the body or clumsiness of limbs, disturbance 
of vision, seizures, speech problems, changes in thinking, memory, and orientation leading 
to confusion and personality changes. Diagnosis of PML is clinical, brain scan including 
gadolinium-enhanced MRI and cerebrospinal fluid analysis for JC viral DNA.  
 
It is most important withhold natalizumab dosing immediately at the first sign or symptom 
suggestive of PML.  
 
Herpes encephalitis and meningitis 
Natalizumab increases the risk of developing encephalitis and meningitis caused by 
herpes simplex and varicella zoster viruses. If it occurs, this treatment should be 
discontinued and appropriate treatment for herpes encephalitis or meningitis will be 
administered. 
 
Hypersensitivity and antibody formation 
Hypersensitivity reactions have occurred in patients receiving natalizumab, including 
serious systemic reactions at an incidence of <1%. These reactions usually occur within 
two hours of the start of the infusion. Symptoms associated with these reactions can 
include urticaria, dizziness, fever, rash, rigors, pruritus, nausea, flushing, hypotension, 
dyspnoea and chest pain. Generally, these reactions are associated with antibodies to 
natalizumab. Antibodies may be detected and confirmed with sequential serum antibody 
tests. The treatment will be discontinued if hypersensitivity reaction or antibody formation 
is detected. 
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Laboratory test abnormalities 
Natalizumab may induce reduction in circulating lymphocytes, monocytes, eosinophils, 
basophils and nucleated red blood cells. Changes persist during treatment period but 
return to baseline levels usually within 16 weeks after the last dose.  
 
Hepatotoxicity 
Clinically significant liver injury, including acute liver failure requiring transplant, has been 
reported, although very few cases, in patients treated with natalizumab. The treatment will 
be discontinued in patients with evidence of significant liver injury. 
 
8.2 Interferon β-1b  
0.25 mg will be injected by route subcutaneous every-other-day. The initial dose will be 
0.0625 mg every-other-day and will increase over 6 weeks period to 0.25 mg (table 3). 
 
 Extavia dose Volume 
Week 1-2 0.0625 mg 0.25 mL 
Week 3-4 0.125 mg 0.50 mL 
Week 5-6 0.1875 mg 0.75 mL 
Week 7 and thereafter 0.25 mg 1 mL 
Table 3. Schedule for dose titration 
8.2.1 Adverse effects 
The most common adverse reactions (incidence ≥ 5%) are: injection site reaction, 
lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver 
enzymes, headache, hypertonia, pain, rash, insomnia, abdominal pain, and asthenia. 
8.2.2 Warnings and precautions 
Anaphylaxis 
Anaphylaxis has been reported as a rare complication of interferon β-1b use but if it 
occurs, the treatment will be discontinued. 
 
Depression and suicide 
Depression and suicide have been reported to occur with increased frequency in patients 
receiving interferon beta products, including interferon β-1b. If a patient develops 
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depression, discontinuation of the therapy should be considered. 
 
Injection site necrosis 
Typically, injection site necrosis occurs within the first 4 months of therapy. The necrotic 
lesions are usually 3 cm and rarely larger areas are affected. The treatment will be 
discontinued if multiple lesions occur. 
 
Flu-like symptom complex 
It is one of the most common side effects among patients using interferon β-1b but the 
incidence decreases over treatment period. Normally the median duration is 7 days. 
Analgesics and antipyretics on treatment days may help flu-like symptoms. 
 
8.3 Acute therapy for relapses during the study 
Relapses may be treated with systemic corticosteroids if clinically necessary and as per 
investigator judgment. The preferred standardized treatment is methylprednisolone sodium 
succinate 1 g, intravenously daily for 3 days. 
 
9. ETHICAL ASPECTS 
 
This clinical trial will be conducted according to the ethical principles which have their 
origin in: 
• Universal Declaration of Human Rights (1948). 
• The Nuremberg Code (1949). 
• The Declaration of Helsinki (1964) and its last update in Edinburgh, Scottish (2000). 
• Ethical and methodological aspects of Good Clinical Practice in the European 
Union. 
 
This study will not be started before the favourable opinion of Ethics Committee in each 
hospital. 
 
All participants should be informed to the fullest extent possible about the study, in 
language and terms they are able to understand. Prior to a patient’s participation in the 
Clinical Trial, the written Informed Consent Form should be signed, name filled in and 
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personally dated by the patient or by the patient’s legally acceptable representative, and by 
the person who conducted the informed consent discussion. A copy of the signed and 
dated written Informed Consent Form will be provided to the patient. 
 
This Clinical Trial will be conducted in compliance with all international laws and 
regulations, and national laws and regulations of the country or countries in which the 
Clinical Trial will be performed, as well as any applicable guidelines. 
 
An insurance will be taken out by the sponsor in order to cover damages or serious side 
effects related to study drugs. This insurance policy will be in accordance with local laws 
and requirements in each country. An insurance certificate will be provided to the Ethics 
committees or Health Authorities in countries requiring this document. 
 
10. BUDGET 
 
The budget will be calculated for each study participant and adjusted for estimated total 
sample size. The study drugs will be provided by the sponsor.  
 
Description Amount Cost Total 
MRI 6 200,00 € 1.200,00 € 
Clinical visits 12 50,00 € 600,00 € 
Nursery visits 24 20,00 € 480,00 € 
Safety laboratory analysis 24 30,00 € 720,00 € 
IgM band determination 1 50,00 € 50,00 € 
  TOTAL          3050,00  €                                                                                                                  
 
Description Cost 
172 participants 524.600,00 € 
Statical analysis 200,00 € 
20% Research centre overhead 104.960,00 € 
 TOTAL STUDY COST          629.760,00 € 
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I. EDSS 
II. MFIS 
III. MSQOL-54 
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Standardised Neurological Examination and Assessment of Kurtzke's Functional Systems 1 and Expanded Disability Status Scale 1
SOURCE DOCUMENT
SUBJECT NO / SUBJECT INITIALS
COUNTRY / CENTRE NO
NAME OF EDSS RATER
DATE OF EXAMINATION1 slightly modified from J. F. Kurtzke, Neurology 1983;33,1444-52
© L. Kappos, Department of Neurology, University Hospitals, 
CH-4031 Basel, Version 06 / 98
neurosTaTu s
1 neurosTaTu s
To ensure unbiased EDSS assessment, the EDSS rater should
not inquire about the patients' condition except as necessary
to perform the EDSS assessment.
Patients must be observed to walk the required distance.
NEUROSTATUS ( NS )
In the Neurostatus «signs only» is noted when the examination
reveals signs of which the patient is unaware.
FUNCTIONAL SYSTEMS ( FS )
A score of 1 in the Functional Systems implies that the patient is
not aware of the deficit and that the deficit or sign does not 
interfere with normal daily activities (with the exceptions of optic,
vegetative and cerebral functions).
EXPANDED DISABILITY STATUS SCALE ( EDSS )
EDSS should not be lower than the highest score of the FS. 
Symptoms which are not MS-related will not be taken 
into consideration for assessments, but should be noted. 
In the definitions of EDSS grades 6.0 and 6.5 both a description
of assistance required and of the walking range are included. 
In general, the distinction of bilateral versus unilateral assistance
required to walk overrules the walking range. 
However, the following exceptions are suggested,
If a patient is able to walk considerably longer than 100 m with
two sticks, crutches or braces he is in grade 6.0.
If a patient is able to walk more than 10 m and less than 100 m
with two sticks, crutches or braces he is in grade 6.5.
If a patient needs assistance by another person (as opposed to
one stick, crutch or brace) and/or is not able to walk more than
50 m with one stick, crutch or brace he is in grade 6.5.
GENERAL GUIDELINES
2 neurosTaTu s
Definitions
Visual acuity
The visual acuity score is based upon the line on the Snellen
chart at 20 feet (5 m) for which the patient makes no more than
one error (use best available correction).
Fields
0 = normal
1 = signs only, deficits present only on formal testing
2 = moderate, patient aware of deficit, but incomplete 
hemianopsia on examination
3 = marked, complete homonymous hemianopsia or equivalent
Scotoma
0 = none
1 = small, detectable only on formal (confrontational) testing
2 = large, spontaneously reported by patient
Disc pallor
0 = not present
1 = present
VISUAL ( OPTIC ) FUNCTIONS
OPTIC FUNCTIONS OD OS
Visual acuity (corrected)
Visual fields
Scotoma
Disc pallor
FUNCTIONAL SYSTEM SCORE
0 = normal
1 = disc pallor and/or mild scotoma and/or visual 
acuity of worse eye ( corrected ) less than 30/30 (1.0 ) 
but better than 20/30 ( 0.67)
2 = worse eye with large scotoma and/or maximal 
visual acuity (corrected) of 20/30 to 20/59 (0.67–0.34)
3 = worse eye with large scotoma or moderate 
decrease in fields and/or maximal visual acuity 
(corrected) of 20/60 to 20/99 ( 0.33 – 0.2 )
4 = worse eye with marked decrease of fields 
and/or maximal visual acuity (corrected) of 20 /100
to 20 / 200 ( 0.1– 0.2 ); grade 3 plus maximal acuity 
of better eye of 20 / 60 ( 0.3 ) or less
5 = worse eye with maximal visual acuity (corrected) 
less than 20 / 200 ( 0.1); grade 4 plus maximal acuity 
of better eye of 20 / 60 ( 0.3 ) or less
6 = grade 5 plus maximal visual acuity of better eye 
of 20 / 60 ( 0.3 ) or less
3 neurosTaTu s
Definitions
Assessment of impairment/disability
0 = normal
1 = signs only
2 = mild, clinically detectable numbness, facial weakness, 
dysarthria or cranial nerve deficits of which patient is aware
3 = moderate, diplopia with incomplete paralysis of any 
eye movement, impaired discrimination of sharp/dull in 1 or 2
trigeminal branches, trigeminal neuralgia, weakness of eye 
closure, cannot hear finger rub and/or misses several whispered
numbers, obvious dysarthria during ordinary conversation 
impairing comprehensibility
4 = severe, complete loss of movement of either eye in one 
direction, impaired discrimination of sharp/dull or complete loss
of sensation in the entire distribution of one or both trigeminal
nerves, unilateral or bilateral facial palsy with lagophthalmus or
difficulty with liquids, sustained difficulty with swallowing, 
incomprehensible voice
Nystagmus
0 = normal
1 = signs only
2 = mild, patient feels disturbed
3 = moderate, sustained nystagmus on 30° horizontal or vertical
gaze, but not in primary position
4 = severe, sustained nystagmus in primary position or coarse
persistent nystagmus in any direction interfering with visual
acuity, complete internuclear ophthalmoplegia with sustained
nystagmus of abducting eye, oscillopsia
FUNCTIONAL SYSTEM SCORE
0 = normal
1 = signs only
2a = moderate nystagmus
2b = other mild disability
3a = severe nystagmus
3b = marked extraocular weakness
3c = moderate disability of other cranial nerves
4a = marked dysarthria
4b = other marked disability
5 = inability to swallow or speak
BRAINSTEM FUNCTIONS
CRANIAL NERVE EXAMINATION
EOM ( extra ocular movements ) impaired
Nystagmus
Trigeminal damage
Facial weakness
Hearing loss
Dysarthria
Dysphagia
Other bulbar signs
4 neurosTaTu s
Definitions * = optional
REFLEXES
0 = absent, 1 = weak, 2 = normal, 3 = exaggerated, 4 = cloniform,
5 = inexhaustible ( indicate difference between R & L by < or > )
Plantar response
0 = flexor, 1 = neutral, 2 = extensor
Cutaneous reflexes
0 = normal, 1 = weak, 2 = absent
* Palmomental reflex
0 = absent, 1 = present
LIMB STRENGTH
The weakest muscle in each group defines the score for that
group. Each movement should be tested, but only pathological
findings should be noted using the BMRC grades. Use of 
functional tests like jumping with one foot, walking on toes or
heels are recommended in order to assess grades 3-5 BMRC.
BMRC Rating scale
0 = no activity, 1 = visible contraction without visible joint 
movement, 2 = visible movements with elimination of gravity, 
3 = movements against gravity possible but impaired, 
4 = movements against resistance possible but impaired, 
5 = normal strength
FUNCTIONAL TESTS
* Position test UE ( upper extremities )
Sinking, 0 = none, 1 = mild, 2 = evident
* Position test LE (lower extremities)
Sinking, 0 = none, 1 = mild, 2 = evident
1 = only separate lifting possible (grades from horizontal position
in hip joints...°)
2 = even separate lifting not possible
* Walking on heals/tiptoes
0 = normal, 1 = impaired, 2 = not possible
* Monopedal hopping
0 = normal, 1 = 6–10 times, 2 = 1– 5 times, 3 = not possible
LIMB SPASTICITY
0 = normal, 1 = mild, barely increased muscular tone after rapid
flexion of an extremity, 2 = moderate, 3 = severe, barely 
surmountable increased spastic tonus after rapid flexion of an
extremity, 4 = contracted
Gait spasticity
0 = normal, 1 = barely perceptible, 2 = evident, minor interference
with function, 3 = permanent shuffling, major interference with
function
PYRAMIDAL FUNCTIONS
FUNCTIONAL SYSTEM SCORE
0 = normal
1 = abnormal signs without disability
2 = minimal disability, patient complains about 
fatiguability in motor tasks and / or BMRC grade 4 in 
one or two muscle groups
3a = mild to moderate paraparesis or hemiparesis, 
full range of movement against gravity
3b = severe monoparesis, refers to BMRC grade 2 or 
less in one muscle group
4a = marked paraparesis or hemiparesis
4b = moderate tetraparesis ( refers to BMRC grade 3 )
4c = Monoplegia
5a = Paraplegia, grade 0 or 1 in all muscle groups of 
the lower limbs
5b = Hemiplegia
5c = Marked tetraparesis ( BMRC grade 2 or less )
6 = Tetraplegia ( grade 0 or 1 in all muscle groups of 
upper and lower limbs )
REFLEXES R > < L
Biceps
Triceps
Radial
Knee
Ankle
Plantar response
Cutaneous reflexes
* Palmomental reflex
LIMB STRENGTH
Shoulder
Elbow flexors
Elbow extensors
Hand / finger flexors
Hand / finger extensors
Hip flexion
Knee flexors
Knee extensors
Foot / toe flexors
Foot / toe extensors
* Position test UE, pronation
* Position test UE, sinking
* Position test LE, sinking
only lifting of single leg possible ° °
* Walking on heals
* Walking on tiptoes
* Hopping on one foot
SPASTICITY
Arm
Leg
Gait
5 neurosTaTu s
Definitions
UE = upper extremities
LE = lower extremities
EO = eyes open
EC = eyes closed
Head tremor, rebound
0 = normal
1 = mild abnormality
2 = moderate abnormality
3 = severe abnormality
Truncal ataxia
0 = none
1 = signs only
2 = mild, swaying with EC
3 = moderate, swaying with EO
4 = severe, unable to sit without assistance
Limb ataxia
0 = none
1 = signs only
2 = mild, tremor or clumsy movements seen easily, minor 
interference with function
3 = moderate, tremor or clumsy movements interfere with 
function in all spheres
4 = severe, most functions are very difficult
Gait ataxia
0 = none
1 = signs only
2 = mild, abnormal balance only on heel or toe walking, 
or walking along a line
3 = moderate, abnormal balance on ordinary walking or while
seated
4 = severe, unable to walk more than a few steps or requires 
support by another person or walking aid because of ataxia
Romberg test
0 = normal
1 = mild, mild insecurity with EC
2 = moderate, not stable with EC
3 = severe, not stable with EO
Straight line walking
0 = without problems
1 = impaired
2 = not possible
Note
The presence of severe gait ataxia alone results in a grade of 3
in the cerebellar FS. If weakness interferes with the testing of 
ataxia, score the patient's actual performance, but also indicate
the possible role of weakness by marking the box marked 'X'.
FUNCTIONAL SYSTEM SCORE 
0 = normal
1 = abnormal signs without disability
2 = mild ataxia
3a = moderate truncal ataxia
3b = moderate limb ataxia
4 = severe ataxia in all limbs or trunk
5 = unable to perform coordinated movements due 
to ataxia
X = weakness ( grade 3 or more on pyramidal ) 
interferes with testing
CEREBELLAR FUNCTIONS
CEREBELLAR EXAMINATION
Head tremor
Truncal ataxia, EO
Truncal ataxia, EC
R L
Tremor/dysmetria UE
Tremor/dysmetria LE
Rapid alternate movements impaired UE
Rapid alternate movements impaired LE
Gait ataxia, EO
Straight line walking, EO
Other, e. g. rebound
Romberg test
6 neurosTaTu s
Definitions * = optional
UE = upper extremities
LE = lower extremities
Superficial sensation – Touch / pain
0 = normal
1 = mild, patient is aware of impaired light touch or pain, 
but able to discriminate sharp / dull
2 = moderate, impaired discrimination of sharp / dull
3 = severe, no discrimination of sharp / dull and / or unable to feel
light touch
4 = complete loss, anaesthesia
Vibration sense
0 = normal
1 = mild, graded tuning fork 5 –7 of 8 ( alternatively ) detects more
than 10 sec. but less than examiner
2 = moderate, graded tuning fork 1– 4 of 8 ( alternatively ) detects
more than 2 sec. but less than 11 sec. 
3 = marked, complete loss of vibration sense
Position sense / Romberg test
0 = normal
1 = mild, 1– 2 incorrect responses on testing, only distal joints
affected / slight stagger during Romberg testing 
2 = moderate, misses many movements of fingers or toes, 
proximal joints affected / unable to stand during Romberg testing
without assistance
3 = marked, no perception of movement / astasia
* Lhermitte
0 = negative
1 = positive
* Paraesthesia ( tingling )
0 = none
1 = present
FUNCTIONAL SYSTEM SCORE
0 = normal
1 = mild vibration or figure-writing decrease only 
in 1 or 2 limbs
2a = mild decrease in touch or pain or position 
sense and / or moderate decrease in vibration 
in 1 or 2 limbs
2b = vibration or figure-writing decrease, alone or 
in 3 or 4 limbs
3a = moderate decrease in touch or pain or position 
sense and/or essentially lost vibration in 1 or 2 limbs
3b = mild decrease in touch or pain and/or 
moderated decrease in all proprioceptive tests 
in 3 or 4 limbs
4a = marked decrease in touch or pain or loss of 
proprioception, alone or combined in 1 or 2 limbs
4b = moderate decrease in touch or pain and/or 
severe proprioceptive decrease in more than 2 limbs
5a = loss (essentially) of sensation in 1 or 2 limbs
5b = moderate decrease in touch or pain and/or loss 
or proprioception for most of the body below the head
6 = sensation essentially lost below the head
SENSORY FUNCTIONS
SENSORY EXAMINATION R L
Superficial sensation ( touch/pain ) UE
Superficial sensation trunk
Superficial sensation LE
Vibration sense UE
Vibration sense LE
Position sense UE
Position sense LE
* Lhermitte
* Paraesthesiae UE
* Paraesthesiae trunk
* Paraesthesiae LE
7 neurosTaTu s
Definitions * = optional
BLADDER
Hesitancy / retention
0 = none
1 = mild, no major impact on lifestyle
2 = moderate, urine retention, frequent UTI
3 = severe, requires catheterisation
4 = loss of function, overflow incontinence
Urgency / incontinence
0 = none
1 = mild, no major impact on lifestyle
2 = moderate, rare incontinence, no more than once a week,
must wear pads
3 = severe, frequent incontinence, several times a week up to
once daily, must wear urinal
4 = loss of function, loss of bladder control
Catheterisation
0 = none
1 = intermittent, up to twice daily
2 = intermittent, > twice daily
3 = constant
Bowel
0 = none
1 = mild, no incontinence, no major impact on lifestyle, 
constipation
2 = moderate, must wear pads or alter lifestyle to be near lavatory
3 = severe, in need of intermittent enemata
4 = complete loss of function
* Sexual dysfunction
0 = none
1 = mild
2 = moderate
3 = severe
4 = loss
FUNCTIONAL SYSTEM SCORE
0 = normal
1 = mild urinary hesitancy, urgency and/or 
constipation
2 = moderate urinary hesitancy and/or urgency 
and/or rare incontinence and/or severe constipation
3 = frequent urinary incontinence or intermittent 
self catheterisation once or twice a day, 
needs constantly enemata or manual measures to 
evacuate bowel
4 = in need of almost constant catheterisation, inter-
. mittent self catheterisation more than twice a day
5 = loss of bladder function, external or indwelling 
catheter
6 = loss of bowel and bladder function
BLADDER AND BOWEL FUNCTIONS
Hesitancy / retention
Urgency / incontinence
Catheterisation
Bowel dysfunction
* Sexual dysfunction
BOWEL / BLADDER FUNCTIONS
8 neurosTaTu s
Definitions
The presence of depression and/or euphoria alone results in a
score of 1 on the cerebral FS, but does not affect the EDSS score.
Depression / euphoria
0 = none
1 = present
Patient complains of depression or is considered depressed or
euphoric by the investigator or «significant other». 
Decrease in mentation
0 = none
1 = mild, difficulties apparent to patient and «significant other»
such as impaired ability to follow a rapid course of association
and of surveying complex matters, impaired judgement in certain
demanding situations, able to handle the daily routine, but no 
tolerance for additional stressors, intermittently symptomatic to
even normal levels of stress, reduced performance, tendency 
toward negligence due to obliviousness or fatigue. 
However, not apparent while taking the history or performing the
routine neurological examination. 
2 = moderate, definite abnormalities on formal mental status
testing, but still oriented to time, place and person
3 = marked, not oriented in 1 or 2 spheres of time, place or 
person, marked effect on lifestyle
4 = dementia, confusion and/or complete disorientation
Fatigue
0 = none
1 = present
Fatigue that interferes with daily activity will be scored with a
maximum of 2 in the FS.
FUNCTIONAL SYSTEM SCORE
0 = normal
1 = mood alteration only 
( does not affect EDSS score )
2 = mild decrease in mentation / fatigue
3 = moderate decrease in mentation
4 = marked decrease in mentation 
5 = dementia
MENTAL STATUS EXAMINATION
Depression
Euphoria
Decrease in mentation
Fatigue
CEREBRAL FUNCTIONS
9 AMBULATION
SYNOPSIS OF FS SCORES
Visual 1
Brainstem
Pyramidal
Cerebellar
Sensory
Bladder/Bowel 2
Mental
Definitions
Actual walking distance without assistance obligatory up to 
500 m ( if possible ). Actual walking distance with assistance 
obligatory up to 150 m ( if possible ). 
In the definitions of EDSS grades 6.0 and 6.5 both a description
of assistance required and of the walking range are included. 
In general, the distinction of bilateral versus unilateral assistance
required to walk overrules the walking range. 
However, the following exceptions are suggested,
If a patient is able to walk considerably longer than 100 m 
( > 120 ) with two sticks, crutches or braces he is in grade 6.0.
If a patient is able to walk more than 10 m and less than 
100 m with two sticks, crutches or braces he is in grade 6.5.
If a patient needs assistance by another person ( as opposed 
to one stick, crutch or brace ) and / or is not able to walk 
more than 50 m with one stick, crutch or brace he is in grade 6.5.
1 For calculation of the EDSS the score of the visual FS is to be
converted as follows, 6 = 4; 5 = 3; 4 = 3; 3 = 2; 2 = 2; 1 = 1.
2 Scores 5 and 6 in the bowel / bladder FS are converted to 4 and
5 respectively.
neurosTaTu s
AMBULATION
Walking range as reported ( without help or sticks )
meters
in min
Able to walk without rest or assistance
> 100 meters, but < 200 meters
> 200 meters, but < 300 meters
> 300 meters, but < 500 meters
> 500 meters
Unrestricted 
Actual distance ( obligatory up to 500 m if possible )
meters
Unable to walk 100 m without constant assistance
Unilateral assistance meters
Cane / crutch
Other
Bilateral assistance meters
Cane / crutch
Other
Other person 
10 neurosTaTu s KURTZKE EXPANDED DISABILITY SCALE ( EDSS )
0 normal neurological exam ( all grade 0 in FS )
1.0 no disability, minimal signs in one FS1 ( i.e. grade 1)
1.5 no disability, minimal signs in more than one FS 1
(more than one grade 1)
2.0 minimal disability in one FS ( one FS grade 2, others 
0 or 1)
2.5 minimal disability in two FS ( two FS grade 2, others 
0 or 1)
3.0 moderate disability in one FS (one FS grade 3, 
others 0 or 1) or mild disability in three or four FS
(three / four FS grade 2, others 0 or 1) though fully 
ambulatory
3.5 fully ambulatory but with moderate disability in one FS
( one grade 3 ) and one or two FS grade 2 ; 
or two FS grade 3; or five FS grade 2 ( others 0 or 1)
4.0 ambulatory without aid or rest for > 500 m; up and about
some 12 hours a day despite relatively severe 
disability consisting of one FS grade 4 ( others 0 or 1 ), 
or combinations of lesser grades exceeding limits 
of previous steps
4.5 ambulatory without aid or rest for > 300 m; up and about
much of the day; characterised by relatively severe 
disability usually consisting of one FS grade 4
or combinations of lesser grades exceeding limits of 
previous steps
5.0 ambulatory without aid or rest for > 200 m ( usual FS
equivalents are one grade 5 alone, others 0 or 1; 
or combinations of lesser grades usually exceeding 
specifications for step 4.5 )
5.5 ambulatory without aid or rest > 100 m
6.0 unilateral assistance ( cane or crutch ) required to 
walk at least 100 m with or without resting
6.5 constant bilateral assistance ( canes or crutches ) 
required to walk at least 20 m without resting
7.0 unable to walk 20 m even with aid, essentially 
restricted to wheelchair; wheels self and transfers 
alone; up and about in wheelchair some 12 h a day
7.5 unable to take more than a few steps; 
restricted to wheelchair; may need some help in 
transfer and in wheeling self
8.0 essentially restricted to bed or chair or perambulated
in wheelchair, but out of bed most of day; retains many
self-care functions; generally has effective use of arms
8.5 essentially restricted to bed much of the day; 
has some effective use of arm(s); retains some self-
care functions
9.0 helpless bed patient; can communicate and eat
9.5 totally helpless bed patient; unable to communicate 
effectively or eat / swallow
10.0 death due to MS
EDSS steps below 4 refer to patients who are fully ambulatory, and the precise step is defined by the functional systems ( FS ) score(s).
EDSS steps between 4.0 and 5.0 are defined by both FS-scores and walking range. In general, the worst of both should determine 
the score. Steps 5.5-8.0 are exclusively defined by ability to ambulate or use wheelchair. 
EDSS should not change by 1.0 step unless there is a change in same direction of at least one step in at least one FS. 
EDSS should not be lower than each of FS ( excepted visual and bowel / bladder FS ).
Actual EDSS
Signature
1 Mental function's grade 1 does not contribute to EDSS-step 
definitions
MFIS-1
Patient's Name:                                       Date:    _____/____/____
                                 month  day  year
ID#:   _____________________ Test#:          1     2     3     4
MODIFIED FATIGUE IMPACT SCALE (MFIS)
Following is a list of statements that describe how fatigue may affect a person.  Fatigue
is a feeling of physical tiredness and lack of energy that many people experience from
time to time.  In medical conditions like MS, feelings of fatigue can occur more often
and have a greater impact than usual.  Please read each statement carefully, and then
circle the one number that best indicates how often fatigue has affected you in this way
during the past 4 weeks.   (If you need help in marking your responses, tell the
interviewer the number of the best response.)  Please answer every question.  If you are
not sure which answer to select, please choose the one answer that comes closest to
describing you.  The interviewer can explain any words or phrases that you do not
understand.
       
Because of my fatigue
during the past 4 weeks....
                                                              
                          Almost
      Never   Rarely   Sometimes    Often    always         
                
1. I have been less alert.   0  1     2 3       4
2. I have had difficulty
paying attention for
long periods of time. 0  1     2 3       4
3. I have been unable to
think clearly. 0  1     2 3       4
4. I have been clumsy
and uncoordinated. 0  1     2 3       4
5. I have been forgetful. 0  1     2 3       4
6. I have had to pace myself
in my physical activities. 0  1     2 3       4
7. I have been less motivated
to do anything that requires
physical effort. 0  1     2 3       4
MFIS-2
Because of my fatigue
during the past 4 weeks....
                                                               
                                                           Almost
           Never   Rarely   Sometimes    Often    always    
8. I have been less motivated
to participate in social
activities. 0  1     2 3       4
 9. I have been limited in my
ability to do things away 
from home. 0  1     2 3       4
10. I have had trouble
maintaining physical effort
for long periods. 0  1     2 3       4
11. I have had difficulty
making decisions. 0  1     2 3       4
12. I have been less motivated to 
do anything that requires 
thinking. 0  1     2 3       4
13. my muscles have felt weak. 0  1     2 3       4
14. I have been physically
uncomfortable. 0  1      2 3       4
15. I have had trouble finishing
tasks that require thinking. 0  1      2 3       4
16. I have had difficulty
organizing my thoughts
when doing things at home
or at work. 0  1      2 3      4
17. I have been less able to
complete tasks that require
physical effort. 0  1      2 3      4 
18. my thinking has been 
slowed down. 0  1      2 3      4
19. I have had trouble
concentrating. 0  1      2 3      4
MFIS-3
Because of my fatigue
during the past 4 weeks....
                                                               
         Almost
           Never   Rarely   Sometimes    Often    always     
20. I have limited my 
physical activities. 0  1      2 3      4
21. I have needed to rest more
often or for longer periods. 0  1      2 3      4
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INSTRUCTIONS: 
 
This survey asks about your health and daily activities.   Answer every question by 
circling the appropriate number (1, 2, 3, ...). 
 
If you are unsure about how to answer a question, please give the best answer 
you can and write a comment or explanation in the margin. 
 
Please feel free to ask someone to assist you if you need help reading or marking the 
form. 
 
 
1. In general, would you say your health is: 
 (circle one number) 
 
Excellent1 
 
Very good.2 
 
Good..3 
 
Fair....4 
 
Poor5 
 
 
 
 
 
2. Compared to one year ago, how would you rate your health in general now? 
 
  (circle one number) 
 
Much better now than one year ago....................... 1 
 
Somewhat better now than one year ago.2 
 
About the same ...................................................... 3 
 
Somewhat worse now than one year ago.............. 4 
 
Much worse now than one year ago ...................... 5 
Copyright© 1995, University of California, Los Angeles 
 
 
3-12. The following questions are about activities you might do during a  typical 
day.  Does your health limit you in these activities?  If so, how much?  
 (Circle 1, 2, or 3 on each line) 
  Yes, 
 Limited 
 a Lot 
 Yes, 
 Limited 
 a Little 
 No, Not 
 Limited 
 at All 
 3. Vigorous activities, such as 
     running, lifting heavy 
     objects, participating in 
     strenuous sports 
 1  2  3 
 4. Moderate activities, such as 
     moving a table, pushing a 
     vacuum cleaner, bowling, or 
     playing golf 
 1 
  2  3 
 5. Lifting or carrying groceries  1  2  3 
 6. Climbing several flights of 
     stairs  1  2  3 
 7. Climbing one flight of stairs  1  2  3 
 8. Bending, kneeling, or 
     stooping  1  2  3 
 9. Walking more than a mile  1  2  3 
10. Walking several blocks  1  2  3 
11. Walking one block  1  2  3 
12. Bathing and dressing 
      yourself  1  2  3 
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13-16. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of your physical 
health?   
 (Circle one number on each line) 
  YES  NO 
13. Cut down on the amount of time you could 
      spend on work or other activities  1  2 
14. Accomplished less than you would like  1  2 
15. Were limited in the kind of work or other 
      activities  1  2 
16. Had difficulty performing the work or other 
      activities 
      (for example, it took extra effort) 
 
 1 
 
 2 
 
 
 
17-19. During the past 4 weeks, have you had any of the following problems with 
your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious).  
 (Circle one number on each line)  
  YES  NO 
17. Cut down on the amount of time you could 
      spend on work or other activities  1  2 
18. Accomplished less than you would like  1  2 
19. Didn't do work or other activities as carefully 
      as usual  1  2 
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20. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbors, or groups? 
  (circle one number) 
 
 Not at all..........................................1 
 
 Slightly ............................................2 
 
 Moderately ......................................3 
     
 Quite a bit .......................................4 
 
 Extremely........................................5 
 
 
 Pain 
 
21. How much bodily pain have you had during the past 4 weeks? 
 
 (circle one number) 
 
 None ...................................... 1 
 
 Very mild................................ 2 
 
 Mild ........................................ 3 
 
 Moderate................................ 4 
 
 Severe ................................... 5 
 
 Very severe............................ 6 
 
 
22. During the past 4 weeks, how much did pain interfere with your 
normal work (including both work outside the home and housework)? 
 
  (circle one number) 
 
 Not at all................................. 1 
 
 A little bit ................................ 2 
 
 Moderately ............................. 3 
 
 Quite a bit .............................. 4 
 
 Extremely............................... 5 
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23-32. These questions are about how you feel and how things have been with you 
during the past 4 weeks.  For each question, please give the one answer that 
comes closest to the way you have been feeling. 
 
How much of the time during the past 4 weeks... (Circle one number on each line) 
 
 All 
 of the 
 Time 
 Most 
 Of the 
  Time 
 A Good 
 Bit of 
 the 
 Time 
 Some 
 of the 
 Time 
 A Little 
 of the 
 Time 
 None 
 of the 
 Time 
23. Did you feel full of pep?  1  2  3  4  5  6 
24. Have you been a very 
      nervous person?  1  2  3  4  5  6 
25. Have you felt so down in 
      the dumps that nothing 
      could cheer you up? 
 1  2  3  4  5  6 
26. Have you felt calm and 
      peaceful?  1  2  3  4  5  6 
27. Did you have a lot of 
      energy?  1  2  3  4  5  6 
28. Have you felt downhearted 
      and blue?  1  2  3  4  5  6 
29. Did you feel worn out?  1  2  3  4  5  6 
30. Have you been a happy 
      person?  1  2  3  4  5  6 
31. Did you feel tired?  1  2  3  4  5  6 
32. Did you feel rested on 
      waking in the morning?  1  2  3  4  5  6 
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33. During the past 4 weeks, how much of the time has your physical 
 health or emotional problems interfered with your social activities  
 (like visiting with friends, relatives, etc.)? 
 
  (circle one number) 
 
 All of the time..........................1 
 
 Most of the time......................2 
 
 Some of the time ....................3 
 
 A little of the time....................4 
 
 None of the time .....................5 
 
 
 
 Health in General 
 
34-37.    How TRUE or FALSE is each of the following statements for you. 
 
(Circle one number on each line)  
  Definitely True 
 Mostly 
 True 
 Not 
 Sure 
 Mostly 
 False 
 Definitely 
 False 
34. I seem to get sick 
      a little easier 
      than other people 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
35. I am as healthy 
      as anybody I  
      know 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
36. I expect my  
      health to get 
      worse 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
37. My health is 
      excellent 
 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
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Health Distress 
 
How much of the time during the past 4 weeks... 
 
(Circle one number on each line) 
 
 All 
 of the 
 Time 
 Most 
 of the 
  Time 
 A Good 
 Bit of 
 the 
 Time 
 Some 
 of the 
 Time 
 A Little 
 of the 
 Time 
 None 
 of the 
 Time 
 
38. Were you discouraged by 
      your health problems? 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
 
 6 
 
39.  Were you frustrated about 
       your health? 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
 
 6 
 
40.  Was your health a worry 
       in your life? 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
 
 6 
 
41.  Did you feel weighed 
       down by your health 
       problems? 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
 
 6 
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Cognitive Function 
 
How much of the time during the past 4 weeks... 
 
(Circle one  number on each line) 
 
 All 
 of the 
 Time 
 Most 
 of the 
  Time 
 A Good 
 Bit of 
 the 
 Time 
 Some 
 of the 
 Time 
 A Little 
 of the 
 Time 
 None 
 of the 
 Time 
42. Have you had difficulty 
      concentrating and  
      thinking? 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
 
 6 
43.  Did you have trouble 
       keeping your attention 
       on an activity for long? 
 
 1 
 
 2 
 
 3 
 
 4 
 
 5 
 
 6 
44.  Have you had trouble   
       with your memory?  1  2  3  4  5  6 
45.  Have others, such as 
       family members or  
       friends, noticed that  
       you have trouble with 
       your memory or problems 
       with your concentration? 
 
 
 1 
 
 
 2 
 
 
 3 
 
 
 4 
 
 
 5 
 
 
 6 
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Sexual Function 
 
46-50. The next set of questions are about your sexual function and your satisfaction with 
your sexual function.  Please answer as accurately as possible about your function 
during the last 4 weeks only. 
 
How much of a problem was each of the following for you during the past 4   
weeks? 
 
   
  (Circle one number on each line) 
 
 
MEN 
 
Not a 
problem 
A Little of 
a 
Problem 
Somewhat 
of a 
Problem 
Very 
Much a 
Problem 
46. Lack of sexual 
interest 
 
1 
 
2 
 
3 
 
4 
47. Difficulty getting 
 or keeping an 
 erection 
 
1 
 
2 
 
3 
 
4 
48. Difficulty having  
 orgasm 
 
1 
 
2 
 
3 
 
4 
49. Ability to satisfy  
 sexual partner 
 
1 
 
2 
 
3 
 
4 
 
 
 
   
  (Circle one number on each line) 
 
 
WOMEN 
 
Not a 
problem 
A Little of 
a 
Problem 
Somewhat 
of a 
Problem 
Very 
Much a 
Problem 
46. Lack of sexual 
interest 
 
1 
 
2 
 
3 
 
4 
47. Inadequate 
lubrication 
 
1 
 
2 
 
3 
 
4 
48. Difficulty having  
 orgasm 
 
1 
 
2 
 
3 
 
4 
49. Ability to satisfy 
 sexual partner 
 
1 
 
2 
 
3 
 
4 
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50. Overall, how satisfied were you with your sexual function during the past 4 weeks? 
 
  (circle one number) 
 
 Very satisfied.................................. 1 
 
 Somewhat satisfied ........................ 2 
 
 Neither satisfied nor 
 dissatisfied ..................................... 3 
  
 Somewhat dissatisfied ................... 4 
 
 Very dissatisfied ............................. 5 
 
 
51. During the past 4 weeks, to what extent have problems with your bowel or bladder function 
interfered with your normal social activities with family, friends, neighbors, or groups? 
  (circle one number) 
 
 Not at all ......................................... 1 
 
 Slightly............................................ 2 
 
 Moderately ..................................... 3 
  
 Quite a bit ....................................... 4 
 
 Extremely ....................................... 5 
 
 
 
52. During the past 4 weeks, how much did pain interfere with your enjoyment of life?  
 
  (circle one number) 
 
 Not at all ......................................... 1 
 
 Slightly............................................ 2 
 
 Moderately ..................................... 3 
  
 Quite a bit ....................................... 4 
 
 Extremely ....................................... 5 
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53. Overall, how would you rate your own quality-of-life? 
 
 
       Circle one number on the scale below:  
 
 
 
 
 
 
 
54. Which best describes how you feel about your life as a whole? 
 
  (circle one number) 
 
 Terrible  ......................................... 1 
 
 Unhappy......................................... 2 
 
 Mostly dissatisfied .......................... 3 
  
 Mixed - about equally  
 satisfied and dissatisfied ................ 4 
 
 Mostly satisfied............................... 5 
 
 Pleased  ........................................ 6 
 
 Delighted ........................................ 7 
 
 
 
 
 
 
 
Scoring Forms for Multiple Sclerosis Quality of Life (MSQOL) -54 
 
 
Table 1 
MSQOL-54 Scoring Form 
 
Table 2 
MSQOL-54 Physical Health Composite Score 
 
Table 3 
MSQOL-54 Mental Health Composite Score 
 
 
Table 1 
MSQOL-54 Scoring Form         
          
           
            Response          Final Score 
Scale/Item Number 1  2   3   4   5   6  Subtotal 0-100 point  
                     scale  
Physical Health           
 3. 0 50 100     _____     
 4. 0 50 100     _____     
 5. 0 50 100     _____     
 6. 0 50 100     _____     
 7. 0 50 100     _____     
 8. 0 50 100     _____     
 9. 0 50 100     _____     
 10. 0 50 100     _____     
 11. 0 50 100     _____     
 12. 0 50 100     _____ 
        Total:     _____ ÷ 10 =  _____  
              
Role limitations due to  
physical problems           
 13. 0 100      _____   
 14. 0 100      _____   
 15. 0 100      _____   
 16. 0 100      _____   
        Total:     _____ ÷ 4 =  _____  
           
Role limitations due to  
emotional problems           
 17. 0 100      _____   
 18. 0 100      _____   
 19. 0 100      _____   
        Total:     _____ ÷ 3 = _____  
           
Pain           
 21. 100 80 60 40 20 0  _____   
 22. 100 75 50 25 0   _____   
 52. 100 75 50 25 0   _____   
        Total:     _____ ÷ 3 = _____  
           
Emotional well-being           
 24. 0 20 40 60 80 100  _____   
 25. 0 20 40 60 80 100  _____   
 26. 100 80 60 40 20 0  _____   
 28. 0 20 40 60 80 100  _____   
 30. 100 80 60 40 20 0  _____   
        Total:     _____ ÷ 5 = _____  
           
Energy           
 23. 100 80 60 40 20 0  _____   
 27. 100 80 60 40 20 0  _____   
 29. 0 20 40 60 80 100  _____   
 31. 0 20 40 60 80 100  _____   
 32. 100 80 60 40 20 0  _____  
        Total:     _____ ÷ 5 = _____  
Table 1 (cont.)            Response          Final Score 
Scale/Item Number 1  2   3   4   5   6  Subtotal 0-100 point 
           
Health Perceptions           
 1. 100 75 50 25 0   _____   
 34. 0 25 50 75 100   _____   
 35. 100 75 50 25 0   _____   
 36. 0 25 50 75 100   _____   
 37. 100 75 50 25 0   _____   
        Total:     _____ ÷ 5 = _____  
           
Social function          
 20. 100 75 50 25 0   _____   
 33. 0 25 50 75 100   _____   
 51. 100 75 50 25 0   _____   
        Total:     _____ ÷ 3 = _____  
           
Cognitive function           
 42. 0 20 40 60 80 100  _____   
 43. 0 20 40 60 80 100  _____   
 44. 0 20 40 60 80 100  _____   
 45. 0 20 40 60 80 100  _____   
        Total:     _____ ÷ 4 = _____  
           
Health distress          
 38. 0 20 40 60 80 100  _____   
 39. 0 20 40 60 80 100  _____   
 40. 0 20 40 60 80 100  _____   
 41. 0 20 40 60 80 100  _____   
        Total:     _____ ÷ 4 =  _____  
              
Sexual function*           
 46. 100 66.7 33.3 0    _____   
 47. 100 66.7 33.3 0    _____   
 48. 100 66.7 33.3 0    _____   
 49. 100 66.7 33.3 0    _____   
        Total:     _____ ÷ 4 =   _____  
           
Change in health           
 2. 100 75 50 25 0                                            _____  
           
Satisfaction with sexual function           
 50. 100 75 50 25 0                          _____  
           
         Response 
Overall quality of life 1   2   3  4   5   6        7       
 53. (multiply response by 10)    _____    
 54. 0 16.7 33.3 50 66.7 83.3 100  _____   
        Total:      _____  ÷ 2 =  _____  
 
Note: The total number of items in each scale is listed as the divisor for each subtotal.  However, due to missing data, 
the divisor might actually be less than that if not every item within a given scale has been answered.  For example, if 
item 38 in the Health Distress scale was left blank and the other 3 items in the scale were answered, then the Total 
score for Health Distress would be divided by 3 (instead of 4) to obtain the Final Score.  
* Males and females can be combined in the analysis even though question 47 is different for the two groups.  The scale 
scores can also be reported separately for males and females.
Table 2 
Formula for calculating MSQOL-54 Physical Health Composite Score 
 
MSQOL-54 Scale Final Scale Score x Weight = Subtotal 
 
Physical function _____  x .17 = _____(a) 
Health perceptions _____  x .17 = _____(b) 
Energy/fatigue _____  x .12 = _____(c) 
Role limitations - physical _____  x .12 = _____(d) 
Pain _____  x .11 = _____(e) 
Sexual function _____  x .08 = _____(f) 
Social function _____  x .12 = _____(g) 
Health distress _____  x .11 = _____(h) 
  
PHYSICAL HEALTH COMPOSITE: Sum subtotals (a) through (h) =  _____ 
 
 
 
 
 
 
 
 
 
 
Table 3 
Formula for calculating MSQOL-54 Mental Health Composite Score 
 
MSQOL-54 Scale Final Scale Score x Weight = Subtotal 
 
Health distress _____  x .14 = _____(a) 
Overall quality of life _____  x .18 = _____(b) 
Emotional well-being _____  x .29 = _____(c) 
Role limitations - emotional _____  x .24 = _____(d) 
Cognitive function  _____   x .15             =       _____(e) 
 
MENTAL HEALTH COMPOSITE: Sum subtotals (a) through (e) =        _____ 
 
INFORMATION SHEET FOR PATIENTS 
 
“Natalizumab versus interferon β-1b to prevent CDMS in 
patients with CIS and poor prognostic factors” 
  
Multicenter study, double blind, randomized in 2 groups: one group will be 
treated with Natalizumab and the other with Interferon β-1b in patients 
with higher risk clinical isolated syndrome (CIS) to develop clinical 
definitive multiple sclerosis (CDMS). 
 
 
Dear Patient,  
 
You have been invited to participate in a research study of comparing 2 
therapies in patients with clinical isolated syndrome (CIS).We are working to 
assess what therapy is most effective to prevent the development from CIS to 
CDMS. Before you decide whether to participate in the study or not, it is 
important that you read this Patient Information Sheet and ask the study doctor 
to explain anything you do not understand. This study has been approved by an 
ethics committee. 
 
Purpose  
 
The main purpose of the study is to see if natalizumab is more effective in the 
treatment of higher risk CIS compared to interferon β-1b . This study also 
attempts to determine whether treatment with natalizumab reduces the MRI 
lesion load, reduces the number of relapses by year and improve the aspects 
related to quality of life. 
 
Treatment Groups  
 
It is expected that about 172 patients are included in this study, approximately in 
30 study centers. 
 
There will be 2 treatment groups in the study, and compare the results of each 
treatment group to find out which treatment works best. To ensure that the 
treatment groups are similar, at baseline will assign you to a random group, 
which means that neither you nor the study doctor can choose their treatment 
group. You have the same probability of being in each of the treatment groups. 
 
To avoid that you know what treatment you are supplied, both groups will 
receive active treatment plus placebo. The placebo has the same appearance 
as the study drug but contains no active drug. 
 
The treatment groups of this study are: 
 
• Group 1: Nearly 86 patients. Natalizumab 300 mg infusion every 4 
weeks plus placebo (sc) every-other day. 
• Group 2: Nearly 86 patients. Interferon β-1b 0.25 mg (sc) every-other 
day plus placebo infusion every 4 weeks. 
 
You will receive the study drug for up to 96 weeks (about 24 months). Neither 
you nor the study doctor or study staff will know if you are receiving natalizumab 
or interferon β-1b. However, in an emergency , we can figure out what treatment 
you are receiving . 
 
Throughout the study, all SC injections (administered every other day) was 
placed on the center under supervision. His first SC injection will be 
administrated in the center. Then, it will be administrated by patients. At hospital 
you will learn how to do it. 
 
The endovenous therapy will be administered at hospital every 4 weeks. 
 
Visits to the center 
 
During the study, you will come at hospital about 24 visits to our center for a 
period of about 24 months. The first visit will be a screening visit to see if you 
meet the conditions for participation in the study. If you meet the conditions for 
participation in the study, return to the center for a baseline visit in the next 4 
weeks, after of additional tests you will be assigned to the treatment group and 
receive their first dose of study drugs. During the study , you will have visits 
every 4 weeks. If you have symptoms of an MS relapse or making other 
significant changes in your health that may be related to use of the study drug, 
additional visits may be necessary to perform additional blood tests.  
 
During the study the following tests shall be performed in some or all visits: 
Blood test, Magnetic resonance imaging brain scan, clinical evaluation and 
quality of life tests. 
 
During the study you will be asked if you have had new symptoms of MS or if 
you will be experiencing worsening symptoms. Any side effects will be 
registered and if some of the laboratory tests show significantly abnormal 
results or other changes in your health, such as infection, your study treatment 
will be temporarily interrupted or permanently discontinued. 
 
Interruption and withdrawal 
 
You may decide to stop your study participation at any time. Before doing it, you 
should discuss your decision with the study doctor . 
 
The treatment with the study drug will be interrupted if:  
 you become pregnant  
 you have symptoms of an allergic reaction to the study drug  
 you show signs of impaired liver function  
 you have a medical reason that necessitates stopping the study drug  
 you not follow the rules of the study 
 
The study doctor may decide to discontinue participation in this study at any 
time. Also withdraw your participation in this study for any of the following 
reasons: the study doctor decides that continuing is not best for you or that it is 
necessary for medical reasons you do not follow the rules of the study 
 
If you need to interrupt the study drug permanently because of liver tests are 
abnormal, you are prompted blood and urine for safety analysis. Your doctor will 
tell you the result of abnormal tests. 
 
If you are removed from the study , you will be asked to return to the study 
center for follow-up visits. 
 
Benefits  
We hope that your participation in the study will be benefit. However, there is no 
guarantee that your MS better for their participation in this study. The results of 
the study can help in the future for people with a similar disorder.  
Risks 
If you think you are having an allergic reaction to medication (develops hives, 
difficulty breathing, swelling of the face, dizziness or other symptoms to explain 
the study staff) should contact the study doctor or seek medical attention 
immediately.  
 
Risks of MRI  
Rarely may cause a severe allergic reaction due to the use of radiological agent 
(gadolinium). The radiological agent may also cause you headaches, dizziness 
or fainting, brownout, nausea, vomiting, sweating, changes in the way things 
taste and symptoms at the injection site. Moreover, in patients with severely 
impaired renal function, some gadolinium contrast agents have been associated 
with a rare disorder, but serious and sometimes fatal (nephrogenic systemic 
fibrosis). If you have experienced any of these symptoms prior to a radiological 
agent, report it to the study doctor. 
 
Risks of Natalizumab 
The most common adverse reactions (incidence ≥ 10%) is headache, fatigue, 
arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, 
vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea and 
rash. 
 
Serious side effects 
 
Progressive multifocal leukoencephalopathy 
Progressive multifocal leukoencephalopathy (PML), an opportunistic viral 
infection of the brain caused by the JC virus (JCV) that typically only occurs in 
patients who are immunocompromised, and that usually leads to death or 
severe disability, has occurred in patients who have received natalizumab. 
 
Three factors that are known to increase the risk of PML in natalizumab-treated 
patients have been identified: 
 Longer treatment duration, especially beyond 2 years. There is limited 
experience in patients who have received more than 6 years of 
natalizumab treatment. 
 Prior treatment with an immunosuppressant (e.g., mitoxantrone, 
azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil). 
 The presence of anti-JCV antibodies. Patients who are anti-JCV 
antibody positive have a higher risk for developing PML. 
 
These factors will be considered in the context of expected benefit when 
initiating and continuing treatment with natalizumab. Only the patients with low 
risk to develop LMP will be included in the study. 
 
Herpes encephalitis and meningitis 
Tysabri increases the risk of developing encephalitis and meningitis caused by 
herpes simplex and varicella zoster viruses. If it occurs, this treatment should be 
discontinued and appropriate treatment for herpes encephalitis or meningitis will 
be administered. 
 
Hypersensitivity and antibody formation 
Hypersensitivity reactions have occurred in patients receiving natalizumab, 
including serious systemic reactions at an incidence of <1%. These reactions 
usually occur within two hours of the start of the infusion. Symptoms associated 
with these reactions can include urticaria, dizziness, fever, rash, rigors, pruritus, 
nausea, flushing, hypotension, dyspnoea and chest pain. Generally, these 
reactions are associated with antibodies to natalizumab. Antibodies may be 
detected and confirmed with sequential serum antibody tests. The treatment will 
be discontinued if hypersensitivity reaction or antibody formation is detected. 
 
Laboratory test abnormalities 
Natalizumab may induce reduction in circulating lymphocytes, monocytes, 
eosinophils, basophils and nucleated red blood cells. Changes persist during 
treatment period but return to baseline levels usually within 16 weeks after the 
last dose.  
 
Hepatotoxicity 
Clinically significant liver injury, including acute liver failure requiring transplant, 
has been reported in patients treated with natalizumab. The treatment will be 
discontinued in patients with evidence of significant liver injury. 
 
Risks of Interferon β-1b  
The most common adverse reaction (incidence ≥ 5%) are: injection site 
reaction, lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, 
increased liver enzymes, headache, hypertonia, pain, rash, insomnia, 
abdominal pain, and asthenia. 
 
  
Serious side effects 
 
Anaphylaxis 
Anaphylaxis has been reported as a rare complication of interferon β-1b use but 
if it occurs, the treatment will be discontinued. 
 
Depression and suicide 
Depression and suicide have been reported to occur with increased frequency 
in patients receiving interferon beta products. If a patient develops depression, 
discontinuation of the therapy should be considered. 
 
Injection site necrosis 
Typically, injection site necrosis occurs within the first 4 months of therapy. The 
necrotic lesions are usually 3 cm and rarely larger areas are affected. The 
treatment will be discontinued if multiple lesions occurs. 
 
Flu-like symptom complex 
It is one of the most common side effect among patients using Extavia but the 
incidence decreases over treatment period. Normally the median duration is 7 
days. Analgesics and antipyretics on treatment days may help flu-like 
symptoms. 
 
Compensation for damages 
It has taken out an insurance, covering all patients participating in this study 
according to the Spanish Royal Decree 223/2004 of 6 February. This insurance 
will cover you if you suffer damages related to the study.  
 
You must tell the study doctor immediately if you believe you have suffered 
damages for participating in this study. Insurance does not cover the normal 
progression of their disease or any damage, injury or complication due to a 
medical condition preexisting. If you have damages related to the study, the 
doctor will decide what medical care you need. 
 
Confidentiality notice  
Your medical information and any information obtained about you during this 
study will be kept confidential in accordance with the Organic Law 15/1999 on 
Protection of Personal Data and the corresponding Royal Decree 1720/2007 
and not will be made public. 
 
 
 
 
 
 
 
 
 
 
INFORMED CONSENT FOR PATIENTS 
“Natalizumab versus interferon β-1b to prevent CDMS in patients with CIS 
and poor prognostic factors” 
Multicenter study, double blind, randomized in 2 groups: one group will be 
treated with Natalizumab and the other with Interferon β-1b in patients with 
higher risk clnical isolated syndrome (CIS) to develop clinical definitive multiple 
sclerosis (CDMS). 
Name of the patient:__________________________     Date of 
birth:_______________ 
                                                   
 I have read this Informed Consent Form or someone has read to me. It is 
written in a language that I understand.  
 I understand what I was asked to do during this study and I have had 
time to think about what the study means for me.  
 I have discussed this with the doctor / study personnel; I asked questions 
about the study and they have been answered satisfactorily.  
 I have received enough information about the study  
 I told the person obtaining consent if I am involved in other medical 
research studies.  
 I have talked to ......................... ( name of the investigator 's / person 
obtaining informed consent )  
 I understand I have to decide if I want to participate in the study and can 
later change my mind, and I can withdraw from the study at any time, 
without giving explanations.  
 I understand that whatever I decide, my care and my legal rights are not 
affected. 
 I understand that I can save a copy of the Patient Information Sheet and 
Informed Consent Form.  
 Voluntarily, I agree to participate in this research study. 
 
Signed and dated by the patient or the patient's legal representative: 
 
Signature:_______________________   Date:____________Hour:_________ 
 
 
